Many studies have used genomic and transcriptomic datasets and immunohistochemical analysis of patient tumors to examine expression of the IGF pathway in breast cancer and its association with clinical outcomes [60,61,62,63,64]. This evidence concerns the gene IGF1 and breast carcinoma.